Pathogenesis and differences from aglycogenoses
The etiology of glycogenoses lies in the congenital absence or decreased activity of enzymes responsible for the mobilization (breakdown) of storage carbohydrates. As a result, glycogen accumulates in excess in target organs. At the same time, the structure of the polymer itself, depending on the specific mutation, may remain completely normal or be pathologically altered.
The main metabolic disorder in this group of diseases is hypoglycemia, which is a drop in blood glucose levels. This occurs because blocked enzymatic pathways prevent tissues from releasing energy substrates into the systemic circulation.
There is also a diametrically opposite group of pathologies called aglycogenoses. Their cause is impaired glycogen synthesis (for example, due to a liver glycogen synthase defect). In this case, the glycogen content in tissues is sharply reduced, but the main metabolic disorder remains the same—patients suffer from severe hypoglycemia.
Classification of glycogen storage diseases
The various types of glycogenoses are differentiated by the nature of the biochemical defect and the localization of the non-functioning enzyme. The most well-known variants are presented in the table:
| Disease name | Defective enzyme | Localization | Manifestations and glycogen structure |
|---|---|---|---|
| Von Gierke disease | Glucose-6-phosphatase | Liver, kidneys | Accumulation of normally structured glycogen, hypoglycemia, acidosis, hyperuricemia |
| Cori disease | Amylo-1,6-glucosidase | Liver, muscles | Accumulation of a polymer with short outer branches |
| Andersen disease | Amylo-1,6-glucosyltransferase | Liver, spleen | Glycogen with long outer branches and infrequent branch points |
| McArdle disease | Glycogen phosphorylase | Skeletal muscles | Accumulation of normally structured muscle glycogen |
| Hers disease | Glycogen phosphorylase | Liver | Accumulation of normally structured liver glycogen |
In addition, there are pathologies in which the function of cAMP-dependent protein kinase or glycogen phosphorylase kinase in the liver is impaired. The clinical picture in these cases is similar to the manifestations of Hers disease.
Von Gierke disease: detailed breakdown (Type I glycogenosis)
The essence of Von Gierke disease is a hereditary defect of the glucose-6-phosphatase enzyme, which is localized in the liver and kidneys. Due to its absence, the final stage of glucose release into the blood is critically impaired.
Metabolic changes in Von Gierke disease develop according to the following scenario:
- Postprandial: Glycogen synthesis occurs without obstacles and is even enhanced due to an abundance of substrates. The polymer massively accumulates in hepatocytes, leading to organ enlargement (hepatomegaly).
- Mobilization of reserves: The breakdown process starts normally. Under the action of glycogen phosphorylase, glucose-1-phosphate is formed, which is then converted into glucose-6-phosphate by the enzyme phosphoglucomutase. But at this stage, the chain is blocked.
- Fasting: In the postabsorptive period (on an empty stomach), the release of free glucose into the blood does not occur or is sharply reduced, since the defective glucose-6-phosphatase cannot cleave the phosphate. Severe hypoglycemia develops.
In parallel, lactate accumulates, causing acidosis, and uric acid levels rise (hyperuricemia).
Differences in carbohydrate metabolism: liver and muscles
To understand the pathogenesis of glycogenoses, it is crucial to know the difference between hepatic and muscular metabolic pathways. Normally, the glucose-6-phosphatase enzyme is absent in skeletal muscles.
This means that muscle glycogen is never used to maintain blood glucose levels throughout the body. It is spent exclusively on local needs—providing energy for muscle contraction. At the same time, the liver serves as the main reservoir, whose task is to nourish the systemic circulation and protect the brain from hypoglycemia between meals. This is precisely why the breakdown of glucose-6-phosphatase in the liver has such catastrophic systemic consequences.
Briefly: answers to topical questions
Which enzyme is defective in Pompe disease (Type II glycogenosis)?
In Pompe disease (Type II glycogenosis), the defective enzyme is alpha-1,4-glucosidase (α-glucosidase, or acid maltase). A mutation in the gene for this enzyme leads to the excessive accumulation of glycogen inside lysosomes. This pathology is the only glycogenosis associated with a lysosomal defect and affects cells of various tissues, most commonly the heart and skeletal muscles.
What types of muscle glycogenoses exist other than McArdle disease?
In addition to McArdle disease, muscle tissue involvement is observed in the following glycogenoses:
- Pompe disease (Type II glycogenosis) — a defect in α-glucosidase (acid maltase), accompanied by the accumulation of glycogen in the lysosomes of skeletal muscles and the heart.
- Cori disease (Type III and IIIa glycogenosis) — a deficiency of the amylo-1,6-glucosidase enzyme, in which abnormal glycogen with short outer branches accumulates in muscle tissue and the liver.
The essence of Von Gierke disease is easy to remember using the "four G's" rule: Von Gierke disease is a defect in Hepatocytes, Glucose-6-phosphatase is broken, and Starvation Hypoglycemia occurs.
Class and exam questions
What is the fundamental difference between glycogenoses and aglycogenoses?
In glycogenoses, carbohydrate breakdown is impaired, causing the polymer to accumulate in excess in tissues. In aglycogenoses, synthesis is impaired, and glycogen content is critically reduced. In both cases, carbohydrate metabolism suffers and hypoglycemia develops.
Why is there no systemic severe hypoglycemia in McArdle's disease?
In this disease, the glycogen phosphorylase defect is localized exclusively in skeletal muscles. Since muscles normally do not release glucose into the blood anyway (they lack glucose-6-phosphatase), systemic glucose levels are maintained by the healthy liver.
In which type of glycogen storage disease does glycogen have abnormally short branches?
This structure is characteristic of Cori disease. It arises due to a defect in amylo-1,6-glucosidase—the enzyme that normally cleaves bonds at the branch points of the polymer.
What else to study on this topic
- Biochemical pathway of glycogen breakdown to glucose-1-phosphate
- Mechanism of development of hyperuricemia and lactic acidosis in Type I glycogenosis
- Specifics of amylo-1,6-glucosyltransferase function and Andersen disease
- Regulation of glycogen metabolism via cAMP-dependent protein kinase
Master the entire topic in the "Biochemistry" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Glycogenoses" and 3,616 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 115 video lessons on the subject
Other topics in the section "Carbohydrate Metabolism"
Free video lessons: biochemistryShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.